Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, April 28, 2022

Elevated Albumin to Globulin Ratio on Day 7 is Associated with Improved Function Outcomes in Acute Ischemic Stroke Patients with Intravenous Thrombolysis

So you should be be working on solutions to increase this ratio. Like some actual useful research?

Elevated Albumin to Globulin Ratio on Day 7 is Associated with Improved Function Outcomes in Acute Ischemic Stroke Patients with Intravenous Thrombolysis>

Authors Yang D, Shen J, Huang H, Wang J, Sun F, Zeng T, Qiu H, Xie H, Chen Y, Li S, Chen Y, Chen G , Weng Y

Received 30 October 2021

Accepted for publication 29 March 2022

Published 26 April 2022 Volume 2022:15 Pages 2695—2705

DOI https://doi.org/10.2147/JIR.S347026

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Ning Quan



Dehao Yang,1,* Jiamin Shen,2,3,* Honghao Huang,2,3,* Jianing Wang,2,3 Fangyue Sun,2,3 Tian Zeng,2,3 Haojie Qiu,2,4 Haobo Xie,2,3 Yilin Chen,2,3 Shengqi Li,2,3 Yiqun Chen,2,3 Guangyong Chen,2 Yiyun Weng5

1Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2Department of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China; 3School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People’s Republic of China; 4School of the Second Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, People’s Republic of China; 5Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Dehao Yang, Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, People’s Republic of China, Email wzmcydh@163.com; Yiyun Weng, Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People’s Republic of China, Email wengyiyun2012@126.com

Background and Purpose: Albumin to globulin ratio (A/G) has been established as a representative biomarker for assessing inflammation and nutritional status. However, the prognostic value of A/G has rarely been reported in acute ischemic stroke (AIS) patients with intravenous thrombolysis (IVT).
Methods: A total of 311 AIS patients who had undergone IVT and completed 3-month follow-up were retrospectively recruited in this study. Albumin (Alb), globulin (Glb) and A/G on admission, within 24 hours after IVT and on day 7 were recorded. Poor outcome was defined as death or major disability (modified Rankin Scale, 3– 6) at 3 months.
Results: Among the 311 cases, 260 patients had admission blood samples, 296 cases had blood samples within 24 hours after IVT and 126 cases had blood samples on day 7. The patients with and without available blood samples were well-balanced. During the first 24 h, we observed A/G to increase significantly compared with baseline whereas at day 7 it was almost back to baseline in patients with a poor outcome. Receiver operating characteristic (ROC) curves analysis showed that A/G had a better performance in discriminating patients at high risk and low risk of a poor outcome than either Alb or Glb alone and carried the highest predictive ability on day 7 (AUC = 0.807). Lower 7-day A/G was independently associated with a poor outcome (per-SD increase, OR = 0.182, 95% CI: 0.074– 0.446).
Conclusion: A/G is an important prognostic indicator for AIS outcomes and merits dynamic monitoring.

Keywords: ischemic stroke, albumin-globulin ratio, intravenous thrombolysis

Introduction

Acute ischemic stroke (AIS), a type of acute cerebrovascular disease, caused by obstruction of blood vessels, is a primary disease contributing to adult morbidity and mortality. Intravenous thrombolysis (IVT) using recombinant tissue plasminogen activator (rt-PA) within 4.5 hours after AIS onset is accepted as a standard therapy for AIS patients nowadays. However, nearly two-thirds of AIS patients do not experience clinical benefit after IVT. This situation creates a need for prognostic factors that would help clinicians identify those AIS patients who are more likely to have poor function outcomes.

Blood biochemistry tests are one of the most commonly prescribed tests. Blood samples could be obtained from AIS patients at an early stage. Total serum protein is composed of albumin (Alb) and globulins (Glb), and abnormalities in the albumin/globulin ratio (A/G) have been observed in different clinical states including malnutrition, cancer, severe liver disease and rheumatic diseases.1–3 A recent study reported that higher serum A/G is associated with better cognitive function in community-dwelling older people.4 Besides, A/G showed a good prognostic value and remained an independent predictor of 90-day and 1-year mortality in patients with chronic heart failure.5 Beamer et al.6 suggested that lower levels of A/G are associated with increased risk for recurrent vascular events after AIS. However, few studies have examined the prognostic value of A/G in AIS patients with r-tPA administration. In the present study, considering Alb, Glb and A/G might be dynamic variables during hospitalization, we aimed to investigate (1) the dynamic profile of Alb, Glb and A/G in AIS patients during the first 7 days; (2) the association between Alb, Glb, A/G and 3-month clinical outcome; and (3) the predictive ability and incremental predictive ability of Alb, Glb and A/G for poor function outcomes in AIS patients treated with IVT r-tPA.

 

No comments:

Post a Comment